Church of PeptidesSearch
Portrait of LL-37
Pilgrims · 1995

LL-37

The Gate Defender

Human innate-immunity research

LL-37 is a human immune-defense peptide studied for antimicrobial activity and wound repair. Controlled research includes topical treatment of venous leg ulcers, but that experience does not establish benefit for systemic injections or general immune enhancement.

Evidence ladder: Controlled human evidence (topical wound studies)Evidence ladder: In-vitro mechanismEducational record
ClassificationPilgrims
Evidence summaryControlled topical trial · no overall healing benefit
OriginHuman innate-immunity research
Scientific record

What the evidence says

Established role or proposed benefit

  • Part of human innate immune defense.
  • Studied for antimicrobial, immune, and wound-related effects.

Side effects, risks, and limits

  • Direct therapeutic use remains experimental.
  • It can also promote inflammation or tissue injury in some contexts.
Doctide’s verdict

The Gate Defender belongs in the immune-biology story. Doctide also records the disappointing overall trial result: a promising mechanism and a subgroup signal cannot substitute for demonstrated benefit in the full study population.

Documented history

Where the real story begins

Clinical development moved from an exploratory topical leg-ulcer trial published in 2014 to a larger phase IIb study published in 2021. The later trial enrolled 148 patients and tested LL-37 alongside compression therapy, providing a more demanding assessment of wound-healing claims. Historical source.

Human innate-immunity research · 1995
Book of the Canon · comic scripture

The laboratory legend

LL-37 guarded the laboratory door against microbes, then accidentally shouted at the furniture. Doctide noted that immune defense and inflammation share a very thin wall.

This bold passage is invented comedy, not scientific or historical fact.
Editorial recordProfile editorial revision: October 4, 2026Prepared under the Church of Peptides evidence standardEditorial review: Church of PeptidesIndependent clinical review: none to dateContent evidence reviewed: September 12, 2026
Evidence ledger

Sources

Source links checked: October 4, 2026. Controlled human research exists for topical wound treatment. It does not establish safety or benefit for systemic or injectable wellness use.

  1. Exploratory randomized topical LL-37 trial, 2014
  2. HEAL LL-37 phase IIb randomized trial, 2021

Fiction disclosure: The bold laboratory legend is invented. The historical and scientific sections are factual summaries; no invented connective events were added.

Educational entertainment only. Not medical advice, diagnosis, dosing guidance, or a recommendation to obtain or use a product.